[go: up one dir, main page]

NO20081973L - PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser - Google Patents

PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser

Info

Publication number
NO20081973L
NO20081973L NO20081973A NO20081973A NO20081973L NO 20081973 L NO20081973 L NO 20081973L NO 20081973 A NO20081973 A NO 20081973A NO 20081973 A NO20081973 A NO 20081973A NO 20081973 L NO20081973 L NO 20081973L
Authority
NO
Norway
Prior art keywords
treatment
pde
urological disorders
combinations
inhibitors
Prior art date
Application number
NO20081973A
Other languages
English (en)
Norwegian (no)
Inventor
Ernst Ulbrich
Peter Sandner
Hanna Tinel
Joachim Hutter
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081973(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20081973L publication Critical patent/NO20081973L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
NO20081973A 2005-09-29 2008-04-24 PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser NO20081973L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05021261 2005-09-29
EP06007776 2006-04-13
PCT/EP2006/009040 WO2007039075A2 (en) 2005-09-29 2006-09-16 Pde inhibitors and combinations thereof for the treatment of urological disorders

Publications (1)

Publication Number Publication Date
NO20081973L true NO20081973L (no) 2008-06-20

Family

ID=37831473

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081973A NO20081973L (no) 2005-09-29 2008-04-24 PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser

Country Status (23)

Country Link
US (1) US20090186896A1 (zh)
EP (1) EP1931797A2 (zh)
JP (1) JP2009509984A (zh)
KR (1) KR20080056250A (zh)
AR (1) AR057867A1 (zh)
AU (1) AU2006299232A1 (zh)
BR (1) BRPI0616633A2 (zh)
CA (1) CA2623657A1 (zh)
CR (1) CR9840A (zh)
DO (1) DOP2006000207A (zh)
EC (1) ECSP088311A (zh)
GT (1) GT200600442A (zh)
IL (1) IL190201A0 (zh)
MA (1) MA29880B1 (zh)
NO (1) NO20081973L (zh)
PE (1) PE20070587A1 (zh)
RU (1) RU2435588C2 (zh)
SG (1) SG166106A1 (zh)
SV (1) SV2009002851A (zh)
TN (1) TNSN08147A1 (zh)
TW (1) TW200804603A (zh)
UY (1) UY29816A1 (zh)
WO (1) WO2007039075A2 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008138483A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
MX2010003193A (es) * 2007-10-02 2010-06-25 Dong A Pharm Co Ltd Composicion y metodo para el tratamiento o prevencion de hiperplasia prostatica benigna y sintomas del tracto urinario inferior.
KR20100108346A (ko) * 2007-11-21 2010-10-06 디코드 제네틱스 이에이치에프 폐 및 심장혈관 질병의 치료를 위한 바이아릴 ｐｄｅ4 억제제
EP2156847A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor.
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
JP2011184433A (ja) * 2010-02-09 2011-09-22 Daiichi Sankyo Healthcare Co Ltd バルデナフィル含有内服液剤組成物
TWI617553B (zh) 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US20160311826A1 (en) * 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA3128680C (en) 2014-08-12 2025-10-07 Childrens Hospital Philadelphia Methods of improving myocardial performance in fontan patients using udenafil compositions
WO2016033776A1 (en) 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
TW201625591A (zh) 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
PL3750538T3 (pl) * 2018-03-23 2024-11-25 Pharmajor International Niehormonalne sposoby męskiej antykoncepcji obejmujące (r) -sylodosynę
JP2022518292A (ja) * 2019-01-23 2022-03-14 パス セラピューティクス，インク． ホスホジエステラーゼ４（ｐｄｅ４）阻害によるてんかんの治療方法
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids
US20250221990A1 (en) * 2023-08-21 2025-07-10 Cmpd Licensing, Llc Topical administration to the oral cavity

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (zh) * 1963-01-16
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
EP0054132B1 (de) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
EP0347146B1 (en) * 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
EP0524180B1 (en) * 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
NZ504436A (en) * 1997-11-12 2001-08-31 Bayer Ag 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
IL150022A0 (en) * 1999-12-24 2002-12-01 Bayer Ag Imidazo [1,3,5] triazinones and the use thereof
US6774128B2 (en) * 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
ATE266407T1 (de) * 2000-10-30 2004-05-15 Lupin Ltd Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
CN100372536C (zh) * 2001-02-15 2008-03-05 田边三菱制药株式会社 在口腔中迅速崩解的片剂
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
EP1392314B1 (de) * 2001-05-09 2006-12-20 Bayer HealthCare AG NEUE VERWENDUNG VON 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on
RU2192864C1 (ru) * 2001-07-23 2002-11-20 Гусева Наталья Борисовна Способ лечения нейрогенной дисфункции мочевого пузыря
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
US20070167450A1 (en) * 2003-11-20 2007-07-19 Astellas Pharma Inc. Agent for treating chronic pelvic pain syndrome
AU2005237607B2 (en) * 2004-04-27 2010-12-16 Medicinova, Inc. Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
WO2006104870A2 (en) * 2005-03-25 2006-10-05 Schering Corporation Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
WO2007002125A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
WO2008138483A1 (en) * 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS

Also Published As

Publication number Publication date
PE20070587A1 (es) 2007-08-17
AR057867A1 (es) 2007-12-26
TNSN08147A1 (en) 2009-07-14
CA2623657A1 (en) 2007-04-12
EP1931797A2 (en) 2008-06-18
RU2435588C2 (ru) 2011-12-10
WO2007039075A2 (en) 2007-04-12
BRPI0616633A2 (pt) 2011-06-28
IL190201A0 (en) 2008-11-03
AU2006299232A1 (en) 2007-04-12
MA29880B1 (fr) 2008-10-03
KR20080056250A (ko) 2008-06-20
SV2009002851A (es) 2009-01-14
DOP2006000207A (es) 2007-07-15
SG166106A1 (en) 2010-11-29
GT200600442A (es) 2007-05-15
RU2008116547A (ru) 2009-11-10
UY29816A1 (es) 2007-04-30
JP2009509984A (ja) 2009-03-12
ECSP088311A (es) 2008-06-30
CR9840A (es) 2008-10-31
WO2007039075A3 (en) 2007-06-21
US20090186896A1 (en) 2009-07-23
TW200804603A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
NO20081973L (no) PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser
WO2006017384A3 (en) Indazoles useful in treating cardiovascular diseases
WO2008019139A3 (en) Inhibitors of pyruvate kinase and methods of treating disease
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2008013589A3 (en) Treatment of ras-expressing tumors
NO20092658L (no) New compounds
TW200724154A (en) Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2008011603A3 (en) Modulating notch1 signaling pathway for treating neuroendocrine tumors
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20071926L (no) Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom.
MY164900A (en) Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia
MX2009011387A (es) Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
HRP20090498T1 (hr) Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja
WO2005074598A3 (en) Nitroxyl progenitor compounds and methods of use
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2006130690A3 (en) Methods and compositions for inducing brown adipogenesis
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
DK1732534T3 (da) Anvendelse af methylenamidderivater ved cardiovaskulære sygdomme
TW200730508A (en) Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same
WO2006102232A3 (en) Dosing regimes for trans-clomiphene
TW200630083A (en) Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application